Company profile: AB2 Bio
1.1 - Company Overview
Company description
- Provider of drug discovery and development of best-in-class therapies for inflammatory diseases, including Tadekinig alfa, a recombinant IL-18 binding protein restoring the IL-18/IL-18BP balance; a proprietary assay to detect and measure free IL-18; and clinical programs in primary HLH (Phase III), secondary HLH/MAS, and adult-onset Still's disease (Phase II).
Products and services
- Clinical Development for Primary HLH: Pivotal Phase III clinical trial for patients with IL‑18‑driven monogenic autoinflammatory conditions, including NLRC4 mutation and XIAP deficiency, focused on primary hemophagocytic lymphohistiocytosis
- Proprietary Assay for IL‑18: Custom-engineered assay detects and measures free IL‑18 in body fluids, aiding identification of IL‑18‑driven diseases
- Tadekinig alfa: Recombinant biologic Interleukin‑18 Binding Protein restores the IL‑18/IL‑18BP balance to treat IL‑18‑mediated inflammatory diseases with large unmet medical needs
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to AB2 Bio
BioSenic
HQ: United States
Website
- Description: Provider of therapies addressing innate immunity, inflammation, and organ/function repair, including arsenic trioxide-based treatments for autoimmune diseases and chronic graft versus host disease (ArsciCor, an oral formulation with rapid gastrointestinal solubilization and optimal bioavailability), cell therapy products for major bone defects and maxillofacial applications, and a Phase III trial of oral arsenic trioxide.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioSenic company profile →
SetPoint Medical
HQ: United States
Website
- Description: Provider of neuroimmune modulation solutions for chronic autoimmune conditions, including a platform that activates immunomodulatory pathways via targeted electrical stimulation to regulate inflammation, and a small vagus nerve stimulation device with integrated circuit, telemetry and rechargeable battery controlled via iPad. Also conducts clinical research, including RESET-RA, a randomized, double-blind rheumatoid arthritis study.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SetPoint Medical company profile →
Forward Pharma
HQ: Denmark
Website
- Description: Provider of biotechnology focused on the immunomodulatory compound dimethyl fumarate and derivatives for pharmaceutical drug applications to treat immune disorders such as multiple sclerosis and psoriasis; founded in 2005 and headquartered in Copenhagen, Denmark.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Forward Pharma company profile →
Acelyrin
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies, identifying, acquiring, and accelerating development and commercialization of candidates including Izokibep (IL-17A inhibitor for psoriatic arthritis and hidradenitis suppurativa), Lonigutamab (subcutaneous anti-IGF-1R for thyroid eye disease), and SLRN-517 (fully human monoclonal targeting c-KIT for chronic urticaria and other mast cell-driven diseases).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Acelyrin company profile →
Aera Therapeutics
HQ: United States
Website
- Description: Provider of a proprietary protein nanoparticle (PNP) delivery platform based on human proteins to deliver genetic medicines across modalities and therapeutic areas, and a therapeutic enzyme platform with novel, compact, programmable gene-editing enzymes to overcome packaging and delivery challenges in gene therapy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aera Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for AB2 Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to AB2 Bio
2.2 - Growth funds investing in similar companies to AB2 Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for AB2 Bio
4.2 - Public trading comparable groups for AB2 Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →